Department of Obstetrics and Gynecology, Dongguan Nancheng Hospital, Dongguan, China.
Department of Obstetrics and Gynecology, Dongguan Maternal and Child Health Care Hospital, Dongguan, China.
J Womens Health (Larchmt). 2024 May;33(5):685-691. doi: 10.1089/jwh.2023.0609. Epub 2024 Apr 1.
This study aims to evaluate the safety and efficacy of erbium:yttrium-aluminum-garnet (Er:YAG) laser treatment in female patients with mild-to-moderate stress urinary incontinence (SUI). From July 2018 to June 2020, 72 female patients with mild-to-moderate SUI were enrolled in this study. A baseline assessment was conducted, which included a 1-hour pad test, the validated International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF), postvoid residual (PVR) testing, pelvic organ prolapse quantification (POP-Q) testing, and a cough stress test. All patients underwent four sessions of Er:YAG laser treatment using a smooth mode. A reassessment was performed 6 months after treatment to evaluate the safety and efficacy of the Er:YAG laser. All patients completed four clinic visits, with a 1-month interval, and were followed up for a minimum of 6 months. No severe adverse reactions were observed during the treatment process. The 1-hour pad test revealed a significant reduction in urinary leakage from baseline (6.30 ± 1.06 g) to the 6-month follow-up (2.70 ± 0.96 g, < 0.001), with 34 of 72 (47.22%) patients achieving negative results. The ICIQ-UI-SF score significantly decreased from baseline to 6 months (10.82 ± 1.38 to 2.96 ± 0.52, < 0.001). PVR experimental results showed a significant decrease in residual urine volume after treatment (103.72 ± 8.61 mL to 43.86 ± 4.92 mL, < 0.001). At the 6-month follow-up, hematoxylin and eosin staining results demonstrated that Er:YAG laser treatment significantly facilitated an increase in the thickness of squamous epithelial cells. The efficacy of Er:YAG laser treatment for SUI was 77.78% (56/72). Several objective and subjective assessments confirmed the safety and efficacy of vaginal smooth mode Er:YAG laser treatment for mild-to-moderate SUI during the 6-month follow-up period. Nonablative Er:YAG laser in the smooth mode is a viable treatment option for SUI patients.
钇-铝-石榴石(Er:YAG)激光治疗轻中度压力性尿失禁(SUI)女性患者的安全性和有效性。2018 年 7 月至 2020 年 6 月,共纳入 72 例轻中度 SUI 女性患者。进行基线评估,包括 1 小时垫试验、经过验证的国际尿失禁咨询问卷-尿失禁简短表(ICIQ-UI-SF)、剩余尿量(PVR)检测、盆腔器官脱垂量化(POP-Q)检测和咳嗽压力试验。所有患者均接受 4 次 Er:YAG 激光平滑模式治疗。治疗后 6 个月进行重新评估,以评估 Er:YAG 激光的安全性和有效性。所有患者均完成 4 次就诊,间隔 1 个月,并至少随访 6 个月。治疗过程中未观察到严重不良反应。1 小时垫试验显示,尿漏从基线(6.30±1.06g)显著减少到 6 个月随访时(2.70±0.96g,<0.001),72 例患者中有 34 例(47.22%)结果为阴性。ICIQ-UI-SF 评分从基线到 6 个月显著降低(10.82±1.38 至 2.96±0.52,<0.001)。PVR 实验结果显示,治疗后残余尿量显著减少(103.72±8.61ml 至 43.86±4.92ml,<0.001)。6 个月随访时,苏木精-伊红染色结果显示,Er:YAG 激光治疗可显著增加鳞状上皮细胞的厚度。Er:YAG 激光治疗 SUI 的有效率为 77.78%(56/72)。几项客观和主观评估证实,阴道平滑模式 Er:YAG 激光治疗轻中度 SUI 在 6 个月随访期间是安全有效的。非剥脱性 Er:YAG 激光平滑模式是治疗 SUI 患者的一种可行选择。